mProX™ Human CCR9 Stable Cell Line

Product Information

Target Protein

CCR9

Target Family

Chemokine Family

Target Protein Species

Human

Host Cell Type

HEP3B;HCCLM3;CHO-K1;HEK293

Target Classification

GPCR Cell Lines

Target Research Area

Immunology Research;Digestive and Renal Research

Related Diseases

Ileitis;Celiac Disease 1

Gene ID

Human: 10803

UniProt ID

Human: P51686

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CCR9, or C-C chemokine receptor type 9, is a protein that has been the subject of extensive research due to its involvement in various physiological and pathological processes. One of the most notable findings is its expression in over 70% of cases of T-ALL, a type of acute lymphoblastic leukemia. Specifically, chimeric antigen receptor (CAR)-T cells targeting CCR9 have shown significant anti-leukemic activity both in vitro and in vivo, suggesting potential therapeutic applications for relapsed or refractory T-ALL cases. Furthermore, CCR9 plays a role in the differentiation and function of CD4 T cells in the gut, impacting tissue homeostasis and immune responses. Another study highlighted the role of CCR9 in the migration of plasmacytoid dendritic cells (pDCs) to the liver, suggesting potential therapeutic applications in acute liver disease. The CCR9 axis has also been implicated in the immunopathology of primary Sjögren's Syndrome, a chronic autoimmune disorder. Overall, the diverse roles of CCR9 in immune responses, cancer, and other diseases make it a promising target for therapeutic interventions and further research.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human CCR9 Stable Cell Line (S01YF-0923-PY42). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Kathleen (Verified Customer)

Is CCR9 only associated with gut-related diseases? Aug 19 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

No, while CCR9 has been studied in relation to gut microbiota and its effects on conditions like premature ovarian failure in mice, it also plays roles in other conditions such as nonalcoholic steatohepatitis and even certain cancers. Aug 19 2021

chat Patricia (Verified Customer)

Does CCR9 play a role in host defense against bacterial infections? Jan 17 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

Yes, studies have shown that CCR9 is involved in host defense against bacterial infections, especially in immune-related organs. Jan 17 2022

Published Data

Fig.1 Silencing CCR9 impedes the proliferation of hepatocellular carcinoma (HCC) cells.

Evaluation of cell proliferation rates through MTT assay at specified time points post cell seeding, with statistical significance denoted as &P<0.05 and *P<0.01.

Ref: Zhang, Zhenhai, et al. "CCR9 as a prognostic marker and therapeutic target in hepatocellular carcinoma." Oncology Reports 31.4 (2014): 1629-1636.

Pubmed: 24481516

DOI: 10.3892/or.2014.2998

Research Highlights

Zhu Y, et al. "Promoting The Recruitment, Engagement, And Reinvigoration of Effector T Cells via ." Advanced materials (Deerfield Beach, Fla.), 2023.
The role of T cells in targeting solid tumors using immunotherapy is crucial, however effectively recruiting them and maintaining their long-term function remains a challenge. A team developed an injectable hydrogel with beta-cyclodextrin (ALG-betaCD) to recruit CCR9(+) CD8(+) T cells, known for their strong anti-tumor activity, by trapping the chemokine CCL25. Additionally, an intravenous injection of an anti-PD1 antibody (Ad-aPD1) would attach to these recruited T cells, resulting in increased accumulation of Ad-aPD1 in the tumor. The ALG-betaCD hydrogel was also able to immobilize other antibodies such as Ad-PD1 and Ad-PDL1, enhancing the interaction between T cells and tumor cells and preventing T cell exhaustion. This treatment approach resulted in improved anti-cancer activity and efficacy in both orthotopic and postsurgical B16-F10 tumor models. This article is protected by copyright and all rights are reserved.
Pubmed: 37807931 DOI: 10.1002/adma.202309667

Jamal M, et al. "CCR9 overexpression promotes T-ALL progression by enhancing cholesterol ." Frontiers in pharmacology, 2023.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease affecting lymphoid progenitor cells, with a higher prevalence in adults. Despite their crucial role in understanding the disease, there is a lack of detailed comparison of the tumorigenic potentials of two commonly used T-ALL cell lines, MOLT4 and JURKAT. In this study, NOD-Prkdc(scid)IL2rgd(ull) (NTG) mice were injected with the cell lines and the homing/infiltration into tissues was investigated. RNA-seq analysis identified differentially expressed genes (DEGs), including CCR9, which was further studied for its role in invasion and metastasis. Overexpression of CCR9 in JURKAT cells (Jurkat-OeCCR9) was confirmed to increase the aggressiveness of the disease. Transcriptome analysis revealed that CCR9 overexpression promoted cholesterol production, which was validated at the protein level. Simvastatin treatment reduced migration in CCR9-overexpressing JURKAT cells, pointing to the significance of cholesterol in T-ALL progression. This study sheds light on the distinct tumorigenic potentials of these cell lines and uncovers the role of CCR9 in regulating cholesterol biosynthesis in T-ALL.
Pubmed: 37745085 DOI: 10.3389/fphar.2023.1257289